Opdualag Europäische Union - Deutsch - EMA (European Medicines Agency)

opdualag

bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanom - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.

Opdualag (80 mg Relatlimab / 240 mg Nivolumab pro 20 ml) Konzentrat zur Herstellung einer Infusionslösung Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

opdualag (80 mg relatlimab / 240 mg nivolumab pro 20 ml) konzentrat zur herstellung einer infusionslösung

bristol-myers squibb sa - relatlimabum, nivolumabum - konzentrat zur herstellung einer infusionslösung - relatlimabum 80 mg, nivolumabum 240 mg, histidinum, histidini hydrochloridum monohydricum, saccharum, polysorbatum 80, acidum penteticum, aqua ad iniectabile ad solutionem pro 20 ml. - fortgeschrittenes melanom - biotechnologika

Opdivo Europäische Union - Deutsch - EMA (European Medicines Agency)

opdivo

bristol-myers squibb pharma eeig - nivolumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; mesothelioma; colorectal neoplasms - antineoplastische mittel - melanomaopdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older. relative to nivolumab monotherapy, an increase in progression free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression. adjuvant treatment of melanomaopdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. non-small cell lung cancer (nsclc)opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. malignant pleural mesothelioma (mpm)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. renal cell carcinoma (rcc)opdivo as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor risk advanced renal cell carcinoma. opdivo in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. classical hodgkin lymphoma (chl)opdivo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant (asct) and treatment with brentuximab vedotin. squamous cell cancer of the head and neck (scchn)opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy. urothelial carcinomaopdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapy. adjuvant treatment of urothelial carcinomaopdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (miuc) with tumour cell pd-l1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of miuc. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy. oesophageal squamous cell carcinoma (oscc)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (oc or gejc)opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. gastric, gastro‑oesophageal junction (gej) or oesophageal adenocarcinomaopdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first‑line treatment of adult patients with her2‑negative advanced or metastatic gastric, gastro‑oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) ≥ 5.

Yervoy Europäische Union - Deutsch - EMA (European Medicines Agency)

yervoy

bristol-myers squibb pharma eeig - ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - antineoplastische mittel - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.  yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 und 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.

ENTEROPORC A Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

enteroporc a

idt biologika gmbh (4006040) - clostridium-perfringens-typ-a-toxoid - lyophilisat und lösungsmittel zur herstellung einer injektionssuspension - clostridium-perfringens-typ-a-toxoid (35001) 125 relative einheit; clostridium-perfringens-typ-a-toxoid (35001) 770 relative einheit - schwein

Virbagen canis B Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

virbagen canis b

virbac tierarzneimittel gmbh (3091569) - borrelia afzelii, inaktiviert; borrelia garinii, inaktiviert - injektionssuspension - borrelia afzelii, inaktiviert (35040) 1 relative einheit; borrelia garinii, inaktiviert (35042) 1 relative einheit - hund

Ingelvac MycoFLEX Injektionssuspension Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ingelvac mycoflex injektionssuspension

boehringer ingelheim vetmedica gmbh (3136680) - mycoplasma hyopneumoniae, stamm j, isolat b-3745, inaktiviert - injektionssuspension - mycoplasma hyopneumoniae, stamm j, isolat b-3745, inaktiviert (38241) 1 relative einheit - schwein

Suvaxyn MH-One Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

suvaxyn mh-one

zoetis deutschland gmbh (4402304) - intramuskuläre anwendung; mycoplasma hyopneumoniae, stamm p-5722-3, inaktiviert - emulsion zur injektion - intramuskuläre anwendung (schwein) - -; mycoplasma hyopneumoniae, stamm p-5722-3, inaktiviert (35152) 1 relative einheit - schwein

Fevaxyn Quatrifel Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

fevaxyn quatrifel

zoetis deutschland gmbh (4402304) - felines panleukopenievirus, stamm cu4, inaktiviert; felines calicivirus, stamm 255, inaktiviert; felines rhinotracheitisvirus, stamm 605, inaktiviert; feline chlamydia psittaci, stamm cello, inaktiviert - emulsion zur injektion - felines panleukopenievirus, stamm cu4, inaktiviert (35295) 8,5 relative einheit; felines calicivirus, stamm 255, inaktiviert (35264) 1,26 relative einheit; felines rhinotracheitisvirus, stamm 605, inaktiviert (35301) 1,39 relative einheit; feline chlamydia psittaci, stamm cello, inaktiviert (35273) 1,69 relative einheit - katze

AquaVac ERM Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

aquavac erm

intervet deutschland gmbh (3067358) - yersinia ruckeri, stamm hagerman typ i, inaktiviert - flüssiges konzentrat - yersinia ruckeri, stamm hagerman typ i, inaktiviert (35216) 75 relativer prozentsatz überlebender tiere nach impfung - forelle